Naoxintong Retards Atherosclerosis by Inhibiting Foam Cell Formation through Activating PPARα Pathway

BACKGROUNDS: We recently reported that Naoxintong (NXT), a China Food and Drug Administration (FDA)-approved cardiac medicine, could reduce the plaque size, but the underlying mechanism remains elusive now. OBJECTIVE: In this study, we investigated the effects of NXT on foam cell accumulation both i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Curr Mol Med
Main Authors: Wang, Zeng, Shi, Huairui, Zhao, Huan, Dong, Zhen, Zhao, Buchang, Weng, Xinyu, Liu, Rongle, Hu, Kai, Zou, Yunzeng, Sun, Aijun, Ge, Junbo
Formato: Artigo
Idioma:Inglês
Publicado em: Bentham Science Publishers 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6463403/
https://ncbi.nlm.nih.gov/pubmed/30734676
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2174/1566524019666190207143207
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados